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(57) ABSTRACT 
The present invention relates to methods and compositions 
for eliciting an immune response against bovine viral 
epitopes. The methods comprise combining at least one heat 
Shock protein with at least one bovine viral epitope to form 
a purified epitope/heat Shock protein complex and adminis 
tration of an immune System Stimulating amount of the 
purified epitope/heat shock protein complex. The composi 
tions comprise, a purified epitope/heat Shock protein com 
pleX comprising at least one bovine viral epitope complexed 
with at least one heat shock protein, and a pharmaceutically 
acceptable carrier, diluent or excipient. 
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METHODS AND COMPOSITIONS FOR 
PROTECTION AGAINST BOVINE WRAL 
DESEASES 
BACKGROUND 
0001. This invention relates to compositions and methods 
of immunizing animals against bovine viral diseases. In 
particular, this invention relates to compositions comprising 
bovine Viral epitopes complexed to a heat shock protein and 
use of Said compositions to immunize animals. More par 
ticularly, this invention relates to compositions comprising 
bovine viral epitopes complexed to heat shock glycoprotein 
96 and the use of Said compositions to immunize animals. 
0002) Numerous vaccine preparations utilizing killed 
(inactivated) or live attenuated viruses are currently avail 
able. Inactivated vaccines are prepared by killing the virus, 
for example, by heat, irradiation or chemical treatment. 
Many inactivated vaccines have not been Satisfactory Since 
they fail to induce humoral immunity of long duration, and 
are incapable of inducing a Satisfactory cell-mediated 
immune response. Attenuated vaccines are prepared by a 
large number of passages on homologous or heterologous 
cells. These passages result in unknown mutations/deletions 
which reduce the pathogenicity of the virus. Alternatively, 
attenuated viruses can be produced by genetic engineering. 
For example, Rijsewijk (U.S. Pat. No. 5,676.951) teaches 
the use of mutant bovine herpesvirus 1(BHV 1) containing 
either a naturally occurring or induced deletion in the 
glycoproteing gene. Attenuated virus vaccines give better 
protection than do killed virus Vaccines, however, attenuated 
vaccines Set up latent infections in vaccinated animals which 
may lead to disease outbreak if the virus reactivates and 
mutates back to a virulent form. 
0003) To overcome the shortcomings of killed or attenu 
ated virus vaccines, attempts have been made to provide 
vaccines based on viral proteins or nucleotide Sequences 
encoding viral proteins. Israel et al. (Vaccine, 6:349-356, 
1988) discloses the use of a BHV 1 glycoprotein vaccine. 
Although administration of this vaccine resulted in high 
antibody titers, it did not confer resistance to an intra nasal 
challenge of BHV 1. 
0004. Because of the ability of many viruses to spread 
from cell to cell, cell mediated immunity, Specifically that 
provided by virus-specific cytotoxic T lymphocytes (CTLs), 
is equally if not more important than neutralizing antibodies 
in protecting the animal from infection. To be recognized by 
CTLS, an infected cell must present the viral peptides in 
association with the Major Histocompatibility Complex 
(MHC) class I molecules on its surface. These CTL peptide 
epitopes are generated by proteoSomal processing of viral 
proteins, and the epitopes are translocated from the cytosol 
into the lumen of the endoplasmic reticulum by Specialized 
transporters called "transporters associated with antigen 
processing” (TAP). The 8 to 10-mer CTL peptide epitopes 
asSociate and form a stable complex with the class I heavy 
chain and the f-microglobulin in the endoplasmic reticu 
lum. The family of peptides bound by a particular class I 
molecule is characterized by the presence of a restricted 
number of "anchor amino acid residues, at particular posi 
tions in the peptide. The "anchor residues and their position 
in the peptides bound by a particular class I allelic product 
constitute the “allele-specific peptide motif (ASPM). Thus, 
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peptides containing ASPMs are especially effective in elic 
iting cell mediated immune responses. The extreme poly 
morphism in the MHC, however, can result in a large 
number of possible alleles, and hence ASPMs. Thus, limit 
ing their potential therapeutic value. 
0005 The discovery of MHC Supertypes in humans pre 
sents a possible solution to the problem presented by MHC 
polymorphism. Supertypes are a group of class I alleles 
which share the same or similar ASPMs. The term super 
motif is used to refer to such motifs which bind to a large 
number of different class I alleles (Sette and Sidney, Curr. 
Opin. Immunol., 10:478-482, 1998). By using peptides 
containing Supermotifs, it is possible to bind epitopes to a 
wide variety of MHC class I molecules, and hence elicit a 
CTL response in a large percentage of individuals in a 
population. 
0006. It is now known that there are other transporters 
involved in epitope presentation. These transporters are 
members of the class of proteins known as heat shock 
proteins (HSPs) (See, Schild et al., Curr. Opin. Immunol, 
11:109-113, 1999). Heat shock proteins are a group of 
proteins whose presence was originally associated with cell 
StreSS, particularly increased temperature. Three major fami 
lies of HSPs hsp60, hsp70 and hsp90 have been identified on 
the basis of their molecular weights (Welch, Scientific 
American, 56-64, May 1993). Many members of these 
families have been found to be induced in response to 
Stressful Stimuli in addition to heat StreSS Such as nutrient 
deprivation, metabolic disruption and intracellular patho 
gens (Welch, Scientific American, 56-64, May 1993; Craig, 
Science, 260:1902-1903, 1993; Gething, et al., Nature, 
355:33-45, 1992; Young, Ann. Rev. Immunol., 8:401-420, 
1990; Lindquist et al., Ann. Rev. Genet., 22:631-677, 1988). 
0007 Heat shock proteins are highly conserved among 
species. For example, hsp70 shows 74% nucleotide 
Sequence homology between yeast and Drosophila, and 85% 
Sequence homology between Drosophila and mice (Moranet 
al., Can. J Biochem. Cell Biol., 61:488-499, 1983). The 
amino acid sequence of human hsp70 is 40% identical to E. 
coli hsp70, dnaK, and 73% identical to Drosophila hsp70 
(Hunt and Morimoto, Proc. Natl. Acad. Sci. USA, 82:6455 
6459, 1985). Thus, the present invention contemplates the 
use of HSPs not only within species (homologous HSP), but 
also across species (heterologous HSPs). 
0008. The evidence that HSPs are involved in immune 
system function came from the observation that HSPs iso 
lated from cancer cells or virus infected cells induced 
protective immunity or cytotoxic T lymphocytes (CTL) to 
the cognate tumor or viral antigen. In contrast, HSPS isolated 
from non-cancerous or uninfected cells elicited no immune 
response. This, combined with the finding that the HSPs do 
not show tumor-associated DNA polymorphism, Suggested 
that HSPs were not immunogenic themselves, but served as 
chaperones for peptides formed during antigen processing 
(Suto and Srivastava, Science, 269:1585-1588, 1995). Mem 
bers of all three HSP families, hsp60, hsp70 and hsp90, have 
been shown to play a role in Stimulation of cell mediated 
immunity (Könen-Waisman et al., J. Infect. Dis., 179:403 
413, 1999; Schild et al., Curr. Opin. Immunol., 11:109-113, 
1999; Blachere et al., J. Exp. Med., 186:1315-1322, 1997; 
Heike et al., J. Leukoc. Biol., 60:153-158, 1996). It has been 
Suggested that HSPS complexed with antigenic peptides are 
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released from virus infected or cancerous cells by lysis of the 
cells during infection or by the action of antibodies or 
nonspecific effectors. The HSP/antigenic peptide complexes 
are then taken up by macrophages or other specialized 
antigen-presenting cells, possibly by a receptor mediated 
mechanism. The complex is then routed to the endogenous 
presentation pathway in the antigen presenting cell and is 
displayed in the context of that cell's MHC class I, where it 
is recognized by CTLS (Srivastava et al., Immunogenetics, 
39:93-98, 1994; Suto and Srivastava, Science, 269:1585 
1588, 1995). More recently, however, this suggestion has 
been questioned (Schild et al., Curr. Opin. Immunol., 
11:109-113, 1999) based on antisense experiments in which 
inhibition of gp96 expression failed to influence the ability 
of cells to present peptides to CTLS (Lammert et al., Eur: J. 
Immnol. 26:875-879, 1996). In addition, it has been found 
that the HSPgp96 cannot bind peptides with charged amino 
acids at P2 and P9 (Spee and Neefjes, Eur: J. Immunol. 
27:2441-2449, 1997) and that gp96 has a hydrophobic 
peptide binding domain (Wearsch et al., Biochemistry, 
37:5709-5719 (1998) thus limiting its peptide binding. 
0009 Glycoprotein 96 (gp96) is a member of the HSP90 
family which is found in the endoplasmic reticulum. Gly 
coprotein 96 preparations isolated from cells expressing a 
transfected cytosolic protein have been found to elicit spe 
cific CTLS against that antigen (Arnold et al., J. Exp. Med., 
182:885-889, 1995). In virus infected cells, gp96 prepara 
tions isolated from cells infected with vesicular stomatitis 
virus (VSV) were found to contain VSV derived peptides 
(Nieland et al., Proc. Natl. Acad. Sci. USA, 93:6135-6139, 
1996). For vaccine production, it has been found that 
gp96-peptide complexes can be generated in Vitro and that 
these complexes elicit immunity by a mechanism apparently 
identical to that Seen with in Vivo generated complexes. 
0.010 Interest in gp96 as an aid to inducing an immune 
response against an antigen comes from Studies which found 
that immunization of mice with gp96 isolated from tumor 
cells provided protection against a Subsequent challenge 
with the tumor cells from which the gp96 was isolated 
(Srivastava et al., Proc. Natl. Acad. Sci. USA, 83:3407-3411, 
1986; Srivastava et al., Adv. Cancer Res., 62:153-177, 
1993). Further studies demonstrated that immunization with 
gp96 molecules from autologous tumor cells elicited CD4" 
and CD8" T cell responses (CD=Cluster of Differentiation) 
against the primary tumor and its metastasises (Tamura et 
al., Science, 278:117-120, 1997. Srivastava teaches the use 
of antigens bound to gp96 for the immunotherapeutic treat 
ment of cancer (U.S. Pat. Nos. 5.830,464, 5,837,251, 5,935, 
576, 5,948,646 and PCT publications WO 97/10001, WO 
98/34641). The same publications disclose the use of gp96/ 
antigen complexes to treat or prevent various infectious 
diseases in humans. Srivastava, however, does not teach or 
Suggest the use of gp96 as an adjuvant to induce CTLS 
against bovine viruses nor does he teach the use of Viral 
sequences that contain ASPMs. In addition, Srivastava does 
not show Stimulation of a humoral as well as a cell-mediated 
response. 
SUMMARY 
0.011) To be effective, it is widely accepted that any 
vaccine preparation must also Stimulate a cell mediated 
immune response, and in particular, the activation of cyto 
toxic T lymphocytes. Presently, attenuated virus Vaccines 
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are used to Stimulate cell mediated immunity. AS discussed 
previously, attenuated viral vaccines are not without prob 
lems. There is a need, therefore, for a composition that is 
capable of eliciting a cell mediated response against bovine 
viruses, but does not involve the use of a live virus. The 
present invention meets that need. 
0012. The present invention insures a T cell response by 
utilizing the heat Shock protein gp96 as an adjuvant. The 
gp96 protein is involved in the association of peptides with 
the MHC type I presentation pathway. Presentation of the 
antigen by the MHC class I complex is thought to be critical 
for eliciting a cell-mediated immune response. The fact that 
gp96 transferS peptides to the class I antigen presentation 
pathway ensures that the peptide epitopes complexed to it 
will be directed to the class I antigen presentation pathway. 
Also, because only peptides are used, there is no problem 
with virus reactivation and Shedding, down regulation of the 
MHC class I surface molecules, and apoptosis of CD4 T 
cells as is seen with modified live virus preparations that are 
currently used to Stimulate cell mediated immunity against 
BHV 1. 
0013 In addition, the method of obtaining epitope/heat 
Shock protein complex from a transfected cell expressing a 
BHV 1 protein alleviates the need for prior identification of 
Specific CTL epitopes. In this method, the epitope/heat 
Shock protein complex contains not only the peptides pre 
Sented by the class I molecules of the transfectant, but also 
the peptides presented by other class I alleles as well. The 
epitope/heat Shock protein complex, therefore, can be used 
to immunize animals with a different MHC background. 
0014) Accordingly, among the aspects of the present 
invention is to provide a method for eliciting an immune 
response in an animal to a bovine virus comprising, com 
bining a bovine Viral epitope and a heat shock protein to 
form a purified epitope/heat Shock protein complex and 
administering an immune System Stimulating amount of Said 
purified epitope/heat shock protein complex to an animal. 
0015. Another aspect of the invention, is a composition 
comprising at least one bovine viral epitope complexed to a 
heat shock protein to form a purified epitope/heat shock 
protein complex, and a pharmaceutically acceptable carrier, 
diluent or excipient. 
0016. In another aspect of the invention, the bovine viral 
epitope contains an allele Specific peptide motif. 
0017. In still another aspect of the invention, the bovine 
Viral epitope contains a Supermotif. 
0018. In yet another aspect of the invention, the allele 
Specific peptide motif is Selected from the group consisting 
of BoLA-A11, BoLA-A20, BoLA-HD1, BoLA-HD6, and 
BOLA-HD7. 
0019. Yet another aspect of the invention provides a 
method for producing a bovine viral CTL epitope/heat shock 
protein complex by transfecting a cell with a nucleotide 
Sequence encoding a bovine viral protein, inducing expres 
Sion of the bovine viral epitope under conditions which also 
induce expression of the heat Shock protein and isolating the 
epitope/heat Shock protein complex from the cells. 
0020 Still another aspect of the invention is a method for 
producing a bovine viral epitope/heat Shock protein complex 
comprising combining an isolated heat shock protein with at 
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least one bovine viral epitope and isolating the complex 
from the uncomplexed epitope and heat shock protein. 
Definitions 
0021 HSP=heat shock protein 
0022 ASPM=allele specific peptide motif 
0023 BSA=bovine serum albumin 
0024 CTL=cytotoxic T lymphocyte 
0025 gp96=heat shock protein glycoprotein 96 
0026 BHV 1=bovine herpesvirus 1 
0027 B-gal=B-galactosidase 
0028 Triton X-100=t-Octylphenoxypolyethoxyetha 
nol 
0029. Tween-20=polyoxyethylenesorbitan monolau 
rate 
0030 CD=Cluster of Differentiation 
0031 moi=multiplicity of infection 
0032 pfu=placque-forming unit 
0033 cpm=counts per minute 
0034) FBS=fetal bovine serum 
0035 PBMC=peripheral blood mononuclear cell 
0.036 AS used herein, “epitope' means a single antigenic 
determinant of an antigenic molecule that Stimulates a 
Specific immune response and against which that response is 
directed. AS used herein, the term includes not only the 
determinant, but also the molecule or fragment of the 
molecule which contains the determinant. 
0037 AS used herein the term “purified epitope/heat 
Shock protein complex’ means that the complex is separated 
from the majority of cell proteins normally associated with 
it or that the complex is synthesized in purified form. Purity 
may be assayed by Standard methods, and will ordinarily be 
at least about 50% pure, generally at least about 60% pure, 
more generally at least about 70% pure, often at least about 
75% pure, more often at least about 80% pure, typically at 
least about 85% pure, more typically at least about 90% 
pure, preferably at least about 95% pure, more preferably at 
least about 98% pure, and most preferably, at least 99% 
pure. The analysis may be weight or molar percentages, 
evaluated, e.g., by gel Staining, spectrophotometry, or ter 
minus labeling. 
0.038. As used herein, "naive” refers to an animal or cell 
that has not been previously exposed to the antigen in 
question. 
0039. As used herein, the term “epitope/heat shock pro 
tein complex refers to a complex containing at least one 
epitope and at least one heat shock protein. 
DETAILED DESCRIPTION 
0040 All publications, patents, patent applications and 
other references cited in this application are herein incor 
porated by reference in their entirety as if each individual 
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publication, patent, patent application or other reference 
were specifically and individually indicated to be incorpo 
rated by reference. 
0041 Applicants have invented methods and composi 
tions for eliciting an immune response in an animal to at 
least one epitope of a bovine virus. In particular, at least one 
epitope of a bovine virus is complexed to a heat shock 
protein which is then administered to an animal in an amount 
that stimulates a measurable immune response (immune 
System stimulating amount). Methods for determining 
Stimulation of the immune System are well known to those 
of ordinary skill in the art. Methods include, but are not 
limited to, the determination of circulating antibodies and/or 
the presence of Specific cytotoxic T lymphocytes. Stimula 
tion of CTLS is thought to be critical to providing immunity 
to viruses. 
0042. The complexes of the present invention can be 
comprised of any combination of heat shock proteins and 
epitopes of bovine viruses in any manner of binding asso 
ciation. In one embodiment, an epitope is non-covalently 
bound to a heat Shock protein. In another embodiment, the 
epitope contains an allele-specific peptide motif (ASPM). In 
yet another embodiment, the epitope contains a Supermotif. 
Suitable heat shock proteins include members of the heat 
Shock protein 60, heat shock protein 70, and heat shock 
protein 90 families. The heat shock protein can be obtained 
from the species to which it is to be administered (homolo 
gous heat shock protein) or it can be from a different species 
(heterologous heat shock protein). In one preferred embodi 
ment, the heat shock protein used is glycoprotein 96 (gp96). 
Glycoprotein 96 is a glycosylated member of the heat shock 
protein 90 family. 
0043 Any protein or peptide derived from the bovine 
Virus of interest can be used in complex with a heat shock 
protein. Examples of Viruses from which proteins can be 
obtained include, but are not limited to, bovine viral diarrhea 
Virus, bovine respiratory Syncytial virus, parainfluenza virus 
III, bovine corona virus, and bovine rota virus. Particularly 
useful are proteins and peptides containing allele-Specific 
peptide motifs (ASPM). Preferred ASPMs include bovine 
lymphocyte antigens (BoLA)-A11 (Hegde et al., Immuno 
genetics, 42:302-303, 1995), BoLA-A20 (Bamford et al., 
Immunol Lett., 45:129, 1995) and BoLA-HD1, -HD6 and 
-HD7 (Gaddum et al., Immunogenetics, 43:238, 1996). 
Because the peptides usually presented by the MHC class I 
complex are 8 to 10-mers, the epitopes used can comprise 
fragments of bovine viral proteins. In one embodiment, 
epitopes comprise peptides of between 5 and 25 amino acids 
in length. In another embodiment, epitopes comprise pep 
tides of between 5 and 15 amino acids in length. In yet 
another embodiment, epitopes comprise peptides of between 
8 and 10 amino acids in length. 
0044) The preparation can be administered to any animal 
which can become infected with a bovine virus. In one 
embodiment, the animal is a ruminant animal, more prefer 
ably a Bovidae and more preferably still a member of the 
genus BOS. 
004.5 The animal can be administered complexes com 
prising a single epitope complexed to HSPS or can be 
administered complexes comprising multiple epitopes com 
plexed to HSPs. The epitope/HSP complexes can be admin 
istered in a single dose or the initial dose can be followed by 
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one or more booster doses. If more than one epitope is used, 
then all epitopes can be given in each administration or, 
alternatively, different epitope/HSP complexes can be given 
at each administration. 
0046) The complexes of the present invention can be 
administered by a variety of routes and methods. Suitable 
routes and methods of administration include orally, 
parenterally, by inhalation Spray, rectally, intradermally, 
transdermally, or topically in dosage unit formulations con 
taining conventional nontoxic pharmaceutically acceptable 
carriers, adjuvants, and vehicles as desired. The term 
parenteral as used herein includes Subcutaneous, intrave 
nous, intramuscular, or intrasternal injection, or infusion 
techniques. In one embodiment, the complexes are admin 
istered by injection and more particularly by intramuscular 
injection. In another embodiment, the complexes are admin 
istered by an intra nasal inhalation spray. In yet another 
embodiment, the complexes can be administered by multiple 
routes, as for example is taught in U.S. Pat. No 5,462,734. 
Methods for the formulation of drugs is well known in the 
art and is discussed in, for example, Hoover, John E., 
Remington's Pharmaceutical Sciences, Mack Publishing 
Co., Easton, Pa. (1975), and Liberman, H. A. and Lachman, 
L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, 
New York, N.Y. (1980). 
0047 Injectable preparations, for example, sterile inject 
able aqueous or oleaginous Suspensions, can be formulated 
according to the known art using Suitable dispersing or 
wetting agents and Suspending agents. The Sterile injectable 
preparation may also be a sterile injectable Solution or 
Suspension in a nontoxic parenterally acceptable diluent or 
Solvent, for example, as a Solution in 1,3-butanediol. Among 
the acceptable vehicles and Solvents that may be employed 
are water, Ringer's Solution, and isotonic Sodium chloride 
Solution. In addition, Sterile, fixed oils are conventionally 
employed as a Solvent or Suspending medium. For this 
purpose, any bland fixed oil may be employed, including 
Synthetic mono- or diglycerides. In addition, fatty acids Such 
as oleic acid are useful in the preparation of injectables. 
Dimethyl acetamide, Surfactants including ionic and non 
ionic detergents, and polyethylene glycols can be used. 
Mixtures of Solvents and wetting agents Such as those 
discussed above are also useful. 
0.048 Suppositories for rectal administration of the com 
pounds discussed herein can be prepared by mixing the 
active agent with a Suitable non-irritating excipient Such as 
cocoa butter, Synthetic mono-, di-, or triglycerides, fatty 
acids, or polyethylene glycols which are Solid at ordinary 
temperatures, but liquid at the rectal temperature, and which 
will therefore melt in the rectum and release the complex. 
0049 Solid dosage forms for oral administration may 
include capsules, tablets, pills, powders, and granules. In 
Such Solid dosage forms, the compounds of this invention 
are ordinarily combined with one or more adjuvants appro 
priate to the indicated route of administration. If adminis 
tered per OS, the compounds can be admixed with lactose, 
Sucrose, Starch powder, cellulose esters of alkanoic acids, 
cellulose alkyl esters, talc, Stearic acid, magnesium Stearate, 
magnesium oxide, Sodium and calcium Salts of phosphoric 
and Sulfuric acids, gelatin, acacia gum, Sodium alginate, 
polyvinylpyrrolidone, and/or polyvinyl alcohol, and then 
tableted or encapsulated for convenient administration. Such 
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capsules or tablets can contain a controlled-release formu 
lation as can be provided in a dispersion of active compound 
in hydroxypropylmethyl cellulose. In the case of capsules, 
tablets, and pills, the dosage forms can also comprise 
buffering agents Such as Sodium citrate, or magnesium or 
calcium carbonate or bicarbonate. Tablets and pills can 
additionally be prepared with enteric coatings. 
0050 For therapeutic purposes, formulations for 
parenteral administration can be in the form of aqueous or 
non-aqueous isotonic Sterile injection Solutions or Suspen 
Sions. These Solutions and Suspensions can be prepared from 
Sterile powders or granules having one or more of the 
carriers or diluents mentioned for use in the formulations for 
oral administration. The compounds can be dissolved in 
water, polyethylene glycol, propylene glycol, ethanol, corn 
oil, cottonseed oil, peanut oil, Sesame oil, benzyl alcohol, 
Sodium chloride, and/or various buffers. Other adjuvants and 
modes of administration are well and widely known in the 
pharmaceutical art. 
0051 Liquid dosage forms for oral administration can 
include pharmaceutically acceptable emulsions, Solutions, 
Suspensions, Syrups, and elixirs containing inert diluents 
commonly used in the art, Such as water. Such compositions 
can also comprise adjuvants, Such as wetting agents, emul 
Sifying and Suspending agents, and Sweetening, flavoring, 
and perfuming agents. 
0052 The amount of epitope/HSP complex that can be 
combined with the carrier materials to produce a single 
dosage form will vary depending upon the patient or animal 
and the particular mode of administration. 
0053 Any suitable method known in the art can be used 
to obtain the bovine viral epitopes or HSPs used in the 
present invention. In general, three methods can be used. In 
one method, the bovine viral epitopes and/or HSPs can be 
isolated from cells which naturally produce the epitopes or 
HSPs. For example, suitable susceptible host cells can be 
infected with the virus of interest and the cells grown in 
culture. In one method, virus is then isolated from the host 
cells and the epitopes isolated from the virus. The isolated 
Virus is treated with a detergent to release the glycoproteins 
located within the lipid envelop of the virion. Alternatively, 
glycoprotein epitopes present on the Surface of infected cells 
can be obtained by detergent-solubilized lysates of infected 
cells rather than from whole virions. The proteins are then 
Separated from the detergent and other debris and the 
individual protein epitopes isolated by methods well known 
to those of ordinary skill in the art. 
0054 Glycoprotein 96 can be purified from any cell that 
naturally expresses the protein. The gp96 can be isolated 
from tissues collected in Vivo or can be from cells grown in 
vitro. If obtained from in vitro cell culture, conditions can be 
manipulated, for example increased temperature, to induce 
increased production of gp96. Various methods for obtaining 
proteins from cells and tissue are known to those of skill in 
the art. These include precipitation by, for example, ammo 
nium Sulfate or ethanol precipitation, acid extraction, anion 
or cation eXchange chromatography, phosphocellulose chro 
matography, hydrophobic interaction chromatography, 
affinity chromatography, hydroxylapatite chromatography, 
lectin chromatography, high performance liquid chromatog 
raphy (HPLC), electrophoresis under native or denaturing 
conditions, isoelectric focusing, and immunoprecipitation. 
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0055. In one embodiment, gp96 is isolated from liver 
cells using the method described by Srivastava, Methods, 
12:165-171, 1997. Briefly, liver cells are homogenized in a 
solution of 30 mM sodium bicarbonate, pH 7, and 1 mM 
phenylmethane-Sulphonyl fluoride (PMSF) using a 
mechanical homogenizer Such as a Polytron. The lysate is 
centrifuged at 2000 g and 4 C. to remove cellular debris. 
The Supernatant is re-centrifuged at 100,000 g for 90 min 
utes at 4 C. Gp96 can be isolated either from the pellet or 
Supernatant from this centrifugation. Purification of gp96 
from the Supernatant is accomplished by bringing the Super 
natant to 50% ammonium sulfate and stirring for 2 to 12 
hours at 4 C. followed by centrifugation at 6000 rpm in a 
SS34 rotor. The Supernatant from this centrifugation is 
brought to 70% ammonium sulfate and centrifuged as for the 
50% cut. The resulting pellet is washed in PBS containing 
70% ammonium Sulfate and then dissolved in 10 volumes of 
PBS containing 2 mM each Ca" and Mg" (Ca/Mg PBS). 
Any undissolved material is removed by centrifugation. The 
dissolved Solution is then added to a concanavalin A chro 
matography column and the bound proteins eluted with 10% 
C-D-methyl mannoside dissolved in Ca/Mg PBS. One third 
of the column volume is applied to the column after which 
the column is sealed and incubated at 37 C. for 30 minutes. 
Following this incubation, five column volumes of eluant 
are applied and the fractions collected. Protein containing 
fractions are then applied to a DEAE ion exchange column 
and the proteins eluted with five volumes of 700 mM NaCl, 
5 mM sodium phosphate, pH 7. For purification of gp96 
from the 100,000 g pellet, the pellet is suspended in 5 
volumes of PBS containing 0.1% octy glucopyranoside and 
placed on ice for 1 hour. The Suspension is then centrifuged 
at 20,000 g for 30 minutes at 4 C. and the detergent 
removed by dialysis against PBS or other suitable method. 
The resulting solution is centrifuged at 100,000 g for 90 
minutes and calcium and magnesium are added to the 
Supernatant to a final concentration of 2 mM each. Further 
purification is carried out as previously described. 
0056. In a second method, epitopes and/or HSPs can be 
made by recombinant DNA technology. Once the nucleotide 
Sequence encoding the viral epitope or HSP of interest is 
known, it can be placed into an expression vector and used 
to transfect a suitable host cell by methods commonly 
known to those of ordinary skill in the art. Sambrook et al., 
Molecular Cloning, A Laboratory Manual, 2, Ed., Cold 
Spring Harbor Press, (1989) and Ausubel et al., Short 
Protocols in Molecular Biology, 2, Ed., John Wiley & Sons 
(1992). Suitable expression vectors include chromosomal, 
non-chromosomal and Synthetic DNA sequences, for 
example, SV 40 derivatives, bacterial plasmids, phage 
DNA; baculovirus; yeast plasmids; vectors derived from 
combinations of plasmids and phage DNA; and viral DNA 
Such as Vaccinia, adenovirus, fowl pox virus, and pseudo 
rabies. In addition, any other vector that is replicable and 
viable in the host may be used. 
0057 The nucleotide sequence of interest may be 
inserted into the vector by a variety of methods. In the most 
common method, the Sequence is inserted into an appropri 
ate restriction endonuclease site(s) using procedures com 
monly known to those skilled in the art and detailed in, for 
example, Sambrook et al., Molecular Cloning, A Laboratory 
Manual, 2, Ed., Cold Spring Harbor Press, (1989) and 
Ausubel et al., Short Protocols in Molecular Biology, 2. 
Ed., John Wiley & Sons (1992). 
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0058. In an expression vector, the sequence of interest is 
operably linked to a Suitable expression control Sequence or 
promoter recognized by the host cell to direct mRNA 
Synthesis. Promoters are untranslated Sequences located 
generally 100 to 1000 base pairs (bp) upstream from the start 
codon of a structural gene that regulate the transcription and 
translation of nucleic acid Sequences under their control. 
Promoters are generally classified as either inducible or 
constitutive. Inducible promoters are promoters that initiate 
increased levels of transcription from DNA under their 
control in response to Some change in the environment, e.g. 
the presence or absence of a nutrient or a change in tem 
perature. Constitutive promoters, in contrast, maintain a 
relatively constant level of transcription. 
0059 A nucleic acid sequence is operably linked when it 
is placed into a functional relationship with another nucleic 
acid Sequence. For example, DNA for a presequence or 
Secretory leader is operatively linked to DNA for a polypep 
tide if it is expressed as a preprotein which participates in the 
Secretion of the polypeptide; a promoter is operably linked 
to a coding Sequence if it affects the transcription of the 
Sequence; or a ribosome binding site is operably linked to a 
coding Sequence if it is positioned So as to facilitate trans 
lation. Generally, operably linked Sequences are contiguous 
and, in the case of a Secretory leader, contiguous and in 
reading phase. Linking is achieved by ligation at restriction 
enzyme Sites. If Suitable restriction sites are not available, 
then Synthetic oligonucleotide adapters or linkers can be 
used as is known to those skilled in the art. Sambrook et al., 
Molecular Cloning, A Laboratory Manual, 2, Ed., Cold 
Spring Harbor Press, (1989) and Ausubel et al., Short 
Protocols in Molecular Biology, 2, Ed., John Wiley & Sons 
(1992). 
0060 Common promoters used in expression vectors 
include, but are not limited to, LTR CMV or SV40 promoter, 
the E. coli lac or trp promoters, and the phage lambda PL 
promoter. Other promoters known to control the expression 
of genes in prokaryotic or eukaryotic cells can be used and 
are known to those skilled in the art. Expression vectors may 
also contain a ribosome binding site for translation initia 
tion, and a transcription terminator. The vector may also 
contain Sequences useful for the amplification of gene 
expression. 
0061 Expression vectors can, and usually do, contain a 
Selection gene or Selection marker. Typically, this gene 
encodes a protein necessary for the Survival or growth of the 
host cell transformed with the vector. Examples of suitable 
markers include dihydrofolate reductase (DHFR) or neomy 
cin resistance for eukaryotic cells, and tetracycline or ampi 
cillin resistance for E. coli. 
0062. In addition, expression vectors can also contain 
marker Sequences operatively linked to a nucleotide 
Sequence for a protein that encode an additional protein used 
as a marker. The result is a hybrid or fusion protein com 
prising two linked and different proteins. The marker protein 
can provide, for example, an immunological or enzymatic 
marker for the recombinant protein produced by the expres 
Sion vector. Numerous Suitable vectors are commercially 
available and are known to those of ordinary skill in the art. 
0063. Once an expression vector has been constructed it 
is placed into a suitable host cell. The host cell will vary with 
the vector used, but in general can be a higher eukaryotic 
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cell, Such as a mammalian cell, or a lower eukaryotic cell 
Such as a yeast cell, or the host can be a prokaryotic cell Such 
as a bacterial cell. Introduction of the construct into the host 
cell can be accomplished by a variety of methods including 
calcium phosphate transfection, DEAE-dextran mediated 
transfection, Polybrene, protoplast fusion, liposomes, direct 
microinjection into the nuclei, Scrape loading, and electropo 
ration. 
0.064 Once transfected host cells are selected based on 
expression of the Sequences encoded by the vector. Selected 
host cells are then grown in culture and induced to produce 
the protein of interest. If the host cell Secretes the protein 
into the culture medium, then the protein can be purified 
from the medium. If the protein is not secreted, the host cells 
can be harvested, lysed and the protein collected from the 
lysate. Proteins can be purified from the cell medium or 
lysate by any Suitable method, Such as those previously 
discussed. 
0065. The vector can be constructed so as to produce a 
Single protein of interest or Several proteins. For example, a 
fusion protein of Several bovine viral epitopes can be 
constructed. The resulting protein can be used as a fusion 
protein or be constructed Such that the epitopes can be 
Separated, for example, by enzymatic cleavage. 
0066. A third method for the production of BHV 1 
epitopes or HSP is by chemical synthesis. Any method of 
peptide Synthesis can be used to practice the present inven 
tion. Chemical Synthesis of peptides is well known to those 
of ordinary skill in the art (Bodanszky, Principles of Peptide 
Synthesis, Springer-Verlag, 1993; Atherton and Sheppard, 
Solid Phase Peptide Synthesis. A Practical Approach, IRL 
Press, 1989; Bodanszky and Bodanszky, The Practice of 
peptide Synthesis, Springer-Verlang, 1984). Modern solid 
phase peptide Synthesis involves the creation of a linear 
peptide chain by the Successive addition of amino acids to a 
growing peptide whose C terminus is covalently linked to a 
Solid Support or resin. Solid-phase peptide Synthesis entails 
three repeated reactions, deprotection, activation, and cou 
pling. In order to prevent unwanted reactions at their alpha 
and Side-chain functionalities, amino acids used in peptide 
synthesis are derivatized or “protected.” Commonly used 
amino protecting groups include the t-butoxycarbonyl group 
(Boc), 9-fluorenylmethyloxycarbonyl (Fmoc), 2-(4- 
biphenylyl)propyl(2)oxycarbonyl (Bpoc), 2-ntiro-phenyl 
Sulfenyl (Nps), and dithia-Succionyl (Dts). During the depro 
tection Step, the protecting group is removed to make the 
alpha-amino group on the end of the growing peptide chain 
available. Activation converts the next amino acid to be 
added into an active ester. During coupling, an amide bond 
is formed between the active ester and the deprotected 
alpha-amino group. The process is repeated until the desired 
peptide is formed. When Synthesis is completed, the Side 
chain protecting groups are removed and the peptide cleaved 
from the Solid phase. In one preferred embodiment, bovine 
Viral epitopes are made by Solid phase peptide Synthesis 
using Standard Fmoc chemistry. 
0067 Viral epitopes useful in the practice of the present 
invention preferably are capable of binding to a heat shock 
protein. Several methods are available to determine binding. 
One method for determination of binding is that used by 
Blachere et al., J. Exp. Med., 186:1315-1322, 1997. In 
general, the epitope to be tested is coupled to a detection 
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moiety. Numerous detection moieties will be readily appar 
ent to those of ordinary skill in the art and include, without 
limitation, radioactive labels, Such as radionuclides, fluoro 
phores or fluorochromes, peptides, enzymes, antigens, anti 
bodies, Vitamins or Steroids. In one embodiment, the detec 
tion moiety is a radionuclide, preferably 'I. The epitope to 
be tested is then incubated with a heat shock protein under 
conditions which promote binding of the epitope to the heat 
Shock protein. In one embodiment, binding is conducted at 
room temperature for 30 minutes in a binding buffer com 
prising 20 mM HEPES, pH 7, 20 mM NaCl and 2 mM 
MgCl2. After the binding reaction, bound and unbound 
labeled epitopes are separated by any Suitable means, for 
example, ultrafiltration or column chromatography. The 
amounts of bound and unbound labeled epitope are then 
determined, Such as in one embodiment, by quantitative 
autoradiography to determine the amount of binding. It will 
be apparent to those skilled in the art, that Screening for 
binding can also be accomplished by using a labeled heat 
Shock protein rather than a labeled epitope. Also, it may be 
possible to determine binding without the use of a label 
coupled to one of the proteins by conducting a binding 
reaction and then Separating the reaction products, by for 
example SDS-PAGE electrophoresis and staining. The bind 
ing of the epitope to the heat shock protein will result in a 
band of increased molecular weight. 
0068. In the present invention, an immune response to a 
Viral epitope is achieved by administration of the epitope in 
combination with a heat Shock protein. In one embodiment, 
the heat shock protein is gp96. The heat shock protein can 
be bound to the epitope by any method known in the art. The 
binding reaction can be conducted in vitro by the method 
described by Blachere et al., J. Exp. Med., 186:1315-1322, 
1997, and discussed above. When the HSP/epitope complex 
is formed in vitro, the ratio of epitope to HSP used to form 
the complex can vary over a wide range. In one embodiment, 
the ratio of epitope to HSP is one part epitope to 100 to 
100,000 parts HSP. In another embodiment, the ratio is one 
part epitope to 1,000 to 50,000 parts HSP. In yet another 
embodiment, the ratio is one part epitope to 10,000 to 25,000 
parts HSP and in still another embodiment, the ratio is one 
part epitope to 12,500 parts HSP. 
0069. Alternatively the epitope-HSP complex can be 
produced in cells. In this embodiment, a host cell that 
expresses a heat shock protein is transfected with a vector 
containing a nucleotide Sequence encoding the viral protein 
or epitope of interest. Methods for producing expression 
vectors and for transforming host cells have been discussed 
previously. Transformed cells are induced to express both 
the endogenous heat Shock protein and the exogenous viral 
epitope. The cells are then harvested, lysed and the epitope 
HSP complexes isolated using Standard protein purification 
techniques Such as those previously discussed. 
0070 The ability of epitope/HSP complexes to elicit 
cytotoxic T lymphocytes can be determined, for example, by 
the 'Cr release assay. Methods for conducting this assay are 
known to those of ordinary skill in the art and can be found, 
for example, in Zatechka et al., Vaccine, 17:686-694, 1999 
and Stikovsky and Henkart, eds., Cytotoxic Cells, Birkauser, 
1993. To generate cytotoxic T lymphocytes, animals are 
twice administered at 1 to 3 week intervals, the candidate 
epitope/HSP complex, the HSP protein alone or the epitope 
alone. Five to ten days after the Second administration, the 
US 2002/01 19163 A1 
animals are euthanized and the Spleens collected. Lympho 
cytes are isolated by any Suitable method, for example, by 
use of a Percoll gradient. Lymphocytes are restimulated in 
Vitro with peptide epitope pulsed, naive, Syngeneic, Stimu 
lator lymphocytes. Stimulator lymphocytes can be prepared, 
for example, by pulsing with from 10 to 200 tug/ml of 
epitope for 1 hour at 37 C. in any suitable culture medium, 
for example, RPMI-1640 Supplemented with 10% fetal 
bovine Serum. In one preferred embodiment, Stimulator 
lymphocytes are pulsed with 100 lug/ml of epitope. The 
pulsed stimulator lymphocytes are irradiated with 2000 Rad. 
Any Suitable Source of radiation can be used. In one embodi 
ment, a 'CO irradiator is used. Responders and stimulators 
are co-cultured at 2x10 cells of each type at 37° C. in an 
appropriate culture medium. 
0071 Target cells are pulsed with candidate epitopes, 
either alone or in combination, as described above for the 
generation of cytotoxic T lymphocytes. Pulsed and non 
pulsed target cells are labeled with 100 uCi of Cr per 
1x10 cells for one hour at 37 C. Labeled cells are then 
washed and incubated at different effector:target cell ratios, 
usually ranging from 1:1 to 100:1 for 4 to 6 hours in a 
suitable culture medium, for example RPMI-1640 contain 
ing 5% fetal bovine Serum. Each assay point is preformed in 
duplicate or triplicate, and appropriate controls to measure 
spontaneous 'Cr release (no lymphocytes (effectors) added) 
and 100% release (lysed target cells). Lysis of target cells 
can be accomplished, for example, by use of a detergent. In 
one embodiment, target cells are lysed by treatment with 
0.5% Triton-X100. Target lysis is determined by measuring 
the amount of Cr in a sample of the culture medium using 
a gamma counter. The percent Specific lysis is calculated as 
follows: 
sample 'Cr release - 
-w spontaneous Cr release 
% specific lysis = x 100 maximum Cr release - 
spontaneous 5 Cr release 
EXAMPLES 
0.072 The following examples are intended to provide 
illustrations of the application of the present invention. The 
following examples are not intended to completely define or 
otherwise limit the scope of the invention. 
Example 1 
Generation of gp96/Epitope Complexes 
0073 Epitopes 
0.074 Epitope peptides are selected to contain ASPMs or 
Supermotifs for the Species in which they are to be injected. 
Epitope peptides are Synthesized using Standard F-moc Solid 
phase chemistry and purified. If desired, the Sequence of the 
epitope peptides can be confirmed by fast atom bombard 
ment-mass Spectrum analysis. Epitope peptides are dis 
solved in distilled water at 2 mg/ml and stored at -70° C. 
until used. 
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0075). Gp96 
0076 Heat shock protein gp96 is obtained from liver 
cells. The procedure used is that described previously. 
Briefly, liver tissue is homogenized in a solution of 30 mM 
Sodium bicarbonate, pH 7, and 1 mM phenylmethane 
sulphonyl fluoride (PMSF), centrifuged and the protein in 
the Supernatant precipitated with 50% and 70% ammonium 
sulfide. The precipitate from the 70% ammonium sulfate cut 
is washed, resuspended and further purified by concanavalin 
A and DEAE chromatography. The gp96 is stored in phos 
phate buffered, pH 7, 700 mM NaCl at -80° C. 
0.077 Gp96/Epitope Binding 
0078. The peptide binding is carried out as previously 
described. Two ng of each epitope peptide is mixed with 25 
lug of gp96 and incubated at 60° C. for 10 minutes in peptide 
binding buffer (20 mM HEPES, pH 7, 20 mM NaCl, 2 mM 
MgCl) to dissociate endogenous liver peptides bound to the 
gp96 molecule. The temperature is then lowered to room 
temperature followed by an additional incubation for 30 
minutes to bind the epitope peptides to the gp96. A control 
complex is made in which bovine serum albumin (BSA) 
replaces the gp96 protein. 
0079 
phocytes 
Immunization and Generation of Cytotoxic T Lym 
0080 Animals are immunized subcutaneously with gp96/ 
epitope complex (25 uggp96/2ng epitope), gp96 alone (25 
pig), epitope peptide alone (2 ng) in 200 ul, or BSA/epitope 
complex (25 ug BSA/2 ng epitope). Animals are given two 
injections Spaced one week apart. One week following the 
last injection, the Spleen is collected and lymphocytes iso 
lated. 
0081 Lymphocytes are restimulated in vitro with the 
epitope peptide pulsed (100 ug/ml) naive, Syngeneic stimu 
lator cells. Stimulator cells are prepared by pulsing with 100 
tug/ml of the epitope peptides in T-cell culture medium 
(RPMI-1640, 2 mM L-glutamine, 0.1 mM MEM nonessen 
tial amino acids, 2.85 g/l NaHCO, 1 mM sodium pyruvate, 
10 mM HEPES, 50 uM 2-mercaptoethanol, 10% FBS) for 1 
hour at 37 C. in a 5% CO2 atmosphere. The pulsed 
stimulator cells are then irradiated (2000 Rad) with a 'Co 
irradiator. Responder and Stimulator cells are co-cultured at 
2x10" cells of each cell type in 25 cm culture flasks in T-cell 
culture medium at 37 C. in a atmosphere of 5% CO. 
0082 'Cr Release Cytotoxicity Assay 
0083) Syngeneic target cells are pulsed with either the 
epitope peptides (100 lug/ml) for 1 hour at 37° C. in 5% CO. 
Pulsed and non-pulsed target cells are labeled with 100 uCi 
of NaCrO per 1x10° cells for 1 hour. Labeled cells are 
washed with RPMI-1640 containing 5% FBS and incubated 
at effector:target ratios of 10:1, 20:1, 40:1 and 8.0:1 for 5 
hours. Target cell lysis is measured by counting 100 ul of 
culture medium in an automated gamma counter. The per 
cent specific lysis is calculated as previously described. 
Spontaneous release is calculated using culture medium 
from Wells containing target cells alone. Maximum release 
is calculated using culture medium from Wells in which the 
cells add been lysed by 0.5% Triton-X100. 
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Example 2 
Cytotoxic T Lymphocyte Recognition in Infected 
Target Cells 
0084. The cytotoxicity assays of Example 1 is conducted 
with targets pulsed with epitope peptides. To confirm that the 
results are applicable to virus infected cells, the cytotoxicity 
assay of Example 1 is repeated with either virus infected or 
mock infected target cells. For mock infection, culture 
medium without virus is used. The assay is performed at an 
effector to target ratio of 20:1. 
Example 3 
Induction of Cytotoxic T-lymphocytes Using 
gp96/epitope Complexes Generated In Cells 
0085 Production of Bovine Viral Epitope Expressing 
Cells 
0.086 BC10ME cells (mouse embryo fibroblasts, H-2) 
are transfected with a Moloney murine retrovirus vector 
containing a gene encoding a viral protein or the B-galac 
tosidase gene to yield BC-Pr or BC-Bgal cells. These cells 
constitutively express either a bovine viral epitope protein or 
B-galactosidase along with gp96. The transfected cells are 
maintained in Dulbecco's Modified Eagle's Medium 
(DMEM) containing 4.5 mg/ml glucose, 10% fetal bovine 
serum, 1 mM sodium pyruvate, 2 mM glutamate, 100 U/ml 
each of penicillin and streptomycin at 37° C. in a 5% CO 
atmosphere. 
0087 
0088 Cells are lysed in four volumes of a solution of 30 
mM sodium bicarbonate, pH 7, and 1 mM phenylmethane 
sulphonyl fluoride (PMSF) using a mechanical homog 
enizer. Complexes are isolated by ammonium Sulfate pre 
cipitation, concanavalin A chromatography, and DEAE 
chromatography as described in Example 1. 
0089) 
phocytes 
0090. Female BALB/c (ByJ) mice (H-2'), 8-12 weeks of 
age, are given two Subcutaneous injections of 25ug of gp96 
isolated from BC-Pr or BC-Bgal cells. The injections are 
given one week apart. Eight days after the Second injection, 
the mice are euthanized, and Spleenocytes collected and 
restimulated in vitro with BC-Pr cells using the methods 
described in Example 1. 
0091 Cr Release Cytotoxicity Assay 
Isolation of Viral Epitope/gp96 Complexes 
Immunization and Generation of Cytotoxic T Lym 
0092 Five to seven days after restimulation, Cr cyto 
toxicity assays are conducted according to the method 
described in Example 1 using BC-Pr and BC-Bgal cells as 
the targets. 
Example 4 
Induction of a Humoral Immune Response by 
gp96/Epitope Complexes 
0093) 
0094. Animals are immunized with two subcutaneous 
injections of 25 lug of BHV 1 g)/gp96 complex isolated 
from BC-Pr cells as described in Example 3. Eight days after 
Immunization 
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that last immunization, blood Samples are collected, the 
plasma separated and presence of viral epitope gld antibod 
ies detected by a radioimmunoassay (RIA). 
Example 5 
In vitro Stimulation of Naive Bovine Splenocytes 
with gp96-Epitope Complexes 
O095 
0.096 Peripheral blood mononuclear cells (PBMCs) are 
isolated from naive calves. PBMCs are stimulated in vitro 
with gp96 derived from BC-Pr cells. Production of BC-Pr 
cells and isolation of gp96 from BC-Pr cells is described in 
Example 3. Cells are Stimulated by adding 25 ug of gp96 
from BC-Pr cells per 1x10 bovine PBMCs in a volume of 
1 ml of T cell culture medium (RPMI-1640, 10% FBS) 
followed by a 1 hour incubation at 37 C. Following 
stimulation, cells are resuspended in 50 ml of T-cell culture 
medium, divided among five, 25 cm tissue culture flasks 
and cultured for Six dayS. At the end of the Six day culture 
period, a 'Cr release cytotoxicity assay is performed as 
described in Example 1. Effector cells are in vitro stimulated 
PBMCs and target cells are either virus infected or mock 
infected autologous PBMCs. Effector to target cell ratios are 
10:1, 20:1, 40:1 and 8.0:1. 
In vitro Stimulation 
Conclusion 
0097. In light of the detailed description of the invention 
and the examples presented above, it can be appreciated that 
the Several aspects of the invention are achieved. 
0098. It is to be understood that the present invention has 
been described in detail by way of illustration and example 
in order to acquaint otherS Skilled in the art with the 
invention, its principles, and its practical application. Par 
ticular formulations and processes of the present invention 
are not limited to the descriptions of the Specific embodi 
ments presented, but rather the descriptions and examples 
should be viewed in terms of the claims that follow and their 
equivalents. While Some of the examples and descriptions 
above include Some conclusions about the way the invention 
may function, the inventor does not intend to be bound by 
those conclusions and functions, but puts them forth only as 
possible explanations. 
0099] It is to be further understood that the specific 
embodiments of the present invention as Set forth are not 
intended as being exhaustive or limiting of the invention, 
and that many alternatives, modifications, and variations 
will be apparent to those of ordinary skill in the art in light 
of the foregoing examples and detailed description. Accord 
ingly, this invention is intended to embrace all Such alter 
natives, modifications, and variations that fall within the 
Spirit and Scope of the following claims. 
What is claimed is: 
1. A method of eliciting an immune response against a 
bovine virus comprising, combining at least one bovine viral 
epitope and at least one heat Shock protein to form a purified 
epitope/heat Shock protein complex, and administering an 
immune System Stimulating amount of Said purified epitope 
heat Shock protein complex to an animal. 
2. The method of claim 1 wherein said bovine viral 
epitope further comprises a Supermotif. 
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3. The method of claim 1 wherein said bovine viral 
epitope further comprises an allele Specific peptide motif. 
4. The method of claim 3 wherein said allele specific 
peptide motif is Selected from the group consisting of 
BoLA-A11, BoLA-A20, BoLA-HD1, BoLA-HD6 and 
BOLA-HD7. 
5. The method claim 1, wherein said bovine viral epitope 
is between 5 and 25 amino acids in length. 
6. The method of claim 1, wherein said bovine viral 
epitope is between 5 and 15 amino acids in length. 
7. The method of claim 1, wherein said viral epitope is 
between 8 and 10 amino acids in length. 
8. The method of claim 1 wherein said epitope is from a 
Virus Selected from the group consisting of bovine viral 
diarrhea virus, bovine respiratory Syncytial virus, parainflu 
enza virus III, bovine corona virus, and bovine rota Virus. 
9. The method of claim 1 wherein said heat shock protein 
is selected from the group consisting of HSP60, HSP 70 and 
HSP 90 families. 
10. The method of claim 9 wherein said heat shock protein 
is gp96 
11. The method of claim 1 wherein said heat shock protein 
is a heterologous heat Shock protein. 
12. The method of claim 1 wherein said heat shock protein 
is a homologous heat shock protein. 
13. The method of claim 1 wherein said epitope/heat 
Shock protein complex is formed in vitro. 
14. The method of claim 1 wherein said epitope/heat 
Shock protein complex is formed in Vivo. 
15. The method of claim 1 wherein said epitope is a 
recombinant epitope 
16. The method of claim 1 wherein said epitope is a 
Synthetic peptide 
17. The method of claim 16, wherein said synthetic 
peptide is Synthesized by Solid phase chemistry. 
18. The method of claim 1 wherein said animal is a 
ruminant. 
19. The method of claim 18 wherein said ruminant is a 
Bovidae. 
20. The method of claim 19 wherein said Bovidae is of the 
genus BoS. 
21. A method for eliciting an immune response to a bovine 
Virus comprising, combining at least one bovine virus allele 
Specific peptide motif containing epitope of at least 8-10 
amino acids long and a heat shock protein gp96 to form a 
purified epitope/heat shock protein complex, and adminis 
tering an immune System Stimulating amount of Saidpurified 
epitope-heat Shock protein complex to a ruminant. 
22. A composition comprising, a purified epitope/heat 
Shock protein complex containing at least one bovine virus 
epitope complexed with at least one heat shock protein, and 
a pharmaceutically acceptable carrier, diluent or excipient. 
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23. The composition of claim 22, wherein said bovine 
Viral epitope further comprises a Supermotif. 
24. The composition of claim 22, wherein said bovine 
Viral epitope further comprises an allele Specific peptide 
motif. 
25. The composition of claim 24, wherein said allele 
Specific peptide motif is Selected from the group consisting 
of BoLA-A11, BoLA-A20, BoLA-HD1, BoLA-HD6 and 
BOLA-HD7. 
26. The composition claim 22, wherein the bovine viral 
epitope is between 5 and 25 amino acids in length. 
27. The composition of claim 22, wherein the bovine viral 
epitope is between 5 and 15 amino acids in length. 
28. The composition of claim 22, wherein the bovine viral 
epitope is between 8 and 10 amino acids in length. 
29. The composition of claim 22 wherein said epitope is 
from a virus Selected from the group consisting of bovine 
Viral diarrhea virus, bovine respiratory Syncytial virus, 
parainfluenza virus III, bovine corona virus, and bovine rota 
Virus. 
30. The composition of claim 22, wherein said heat shock 
protein is selected from the group consisting of HSP60, HSP 
70 and HSP 90 families. 
31. The composition of claim 30 wherein said heat shock 
protein is gp96 
32. The composition of claim 22, wherein said heat shock 
protein is a heterologous heat Shock protein. 
33. The composition of claim 22, wherein said heat shock 
protein is a homologous heat shock protein. 
34. The composition of claim 22, wherein Said epitope/ 
heat shock protein complex is formed in vitro. 
35. The composition of claim 22 wherein said epitope/ 
heat Shock protein complex is formed in Vivo. 
36. The composition of claim 22 wherein said epitope is 
a recombinant epitope 
37. The composition of claim 22 wherein said epitope is 
a Synthetic peptide. 
38. The composition of claim 37 wherein the synthetic 
peptide is Synthesized by Solid phase chemistry. 
39. A composition comprising, a purified epitope/heat 
Shock protein complex containing: 
a gp96 heat shock protein; 
at least bovine Viral epitope of 8-10 amino acids long, Said 
epitope being from a virus Selected from the group 
consisting of bovine viral diarrhea virus, bovine respi 
ratory Syncytial virus, parainfluenza virus III, bovine 
corona virus, and bovine rota Virus, and 
a pharmaceutically acceptable carrier, diluent or exci 
peint. 
